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ABSTRACT
Tristetraprolin (TTP) is a AU-rich element (ARE)
binding protein and exhibits suppressive effects on
cell growth through down-regulation of ARE-
containing oncogenes. The let-7 microRNA has
emerged as a significant factor in tumor suppres-
sion. Both TTP and let-7 are often repressed in
human cancers, thereby promoting oncogenesis
by derepressing their target genes. In this work, an
unexpected link between TTP and let-7 has been
found in human cancer cells. TTP promotes an
increase in expression of mature let-7, which leads
to the inhibition of let-7 target gene CDC34 expres-
sion and suppresses cell growth. This event is
associated with TTP-mediated inhibition of Lin28,
which has emerged as a negative modulator of
let-7. Lin28 mRNA contains ARE within its 30-UTR
and TTP enhances the decay of Lin28 mRNA
through binding to its 30-UTR. This suggests that
the TTP-mediated down-regulation of Lin28 plays a
key role in let-7 miRNA biogenesis in cancer cells.
INTRODUCTION
MicroRNAs (miRNAs) are a class of short ( 21–25nt),
single-stranded, non-coding RNAs. They bind to the
30-untranslated regions (30-UTRs) (1) or protein-coding
exons of speciﬁc messenger RNAs (mRNAs) (2) and
inhibit translation or promote degradation of the tran-
script (3). The expression of miRNA can be controlled
at both the transcriptional and post-transcriptional level.
This regulation is crucial, as aberrant miRNA expres-
sion has been linked to human diseases including
cardiovascular disorders and cancer (4). Most miRNAs
are transcribed by RNA polymerase II as long primary
transcripts, termed pri-miRNAs. However, post-
transcriptional regulation occurs at multiple steps of
miRNA biogenesis, and thus mature miRNA expres-
sion does not always correlate with expression of
pri-miRNA (5,6).
The miRNA let-7 was initially discovered as a critical
regulator of stem-cell differentiation in Caenorhabditis
elegans (7), and is highly conserved across diverse
animal species (8). It functions as a tumor suppressor by
targeting multiple oncogenes and a reduction of let-7 level
is strongly associated with increased tumorigenicity and
poor patient prognosis (9). It has been reported that
mature let-7 appears only after differentiation in embry-
onic stem (ES) cells, while the levels of pri- and pre-let-7
are comparable between undifferentiated and
differentiated ES cells, suggesting post-transcriptional
control in let-7 biogenesis (10,11). Recently, the Lin28
proteins have been identiﬁed as regulatory factors for
let-7 biogenesis (12–14). Mammals have two Lin28
homologs, Lin28a and Lin28b, which are indistinguish-
able from each other in their biochemical activities
(12,14). Lin28 has been reported to interfere with the
Drosha processing of pri-let-7 (14) and Dicer processing
of pre-let-7 (12,13). In the case of the pre-let-7, Lin28 binds
to the terminal loops of the pre-miRNA, recruits a poly
(U) polymerase, terminal (U) transferase (TUT4) which
adds a uridine tail to the 30-end of the pre-miRNA and
*To whom correspondence should be addressed. Tel: +82 52 259 2356; Fax: +82 52 259 1694; Email: jwpark@ulsan.ac.kr
Correspondence may also be addressed to Wha Ja Cho. Tel: +82 52 259 2356; Fax: +82 52 259 1694; Email: wjcho26@ulsan.ac.kr
The authors wish it to be known that, in their opinion, the ﬁrst two authors should be regarded as joint First Authors.
3856–3869 Nucleic Acids Research, 2012, Vol. 40, No. 9 Published online 30 December 2011
doi:10.1093/nar/gkr1302
 The Author(s) 2011. Published by Oxford University Press.
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/
by-nc/3.0), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.triggers its degradation (15–17). In human tumors, Lin28
is up-regulated and reactivated to function as an oncogene
promoting malignant transformation and tumor progres-
sion (18,19). Thus, down-regulation of Lin28 in tumors
that overexpress this gene may provide a means to reacti-
vate the expression of let-7 tumor suppressor (18).
However, the mechanisms that regulate Lin28 expression
are still largely unknown.
Post-transcriptional regulation of gene expression is
also mediated by AU-rich elements (AREs) located in
the 30-UTR of a variety of short-lived mRNAs such as
cytokines and proto-oncogenes (20). The destabilizing
function of AREs is believed to be regulated by ARE
binding proteins (21). One of the best-characterized
ARE-binding proteins is tristetraprolin (TTP) that
promotes degradation of ARE-containing transcripts
(22,23). TTP expression was signiﬁcantly decreased in vari-
ous cancers (24), which correlates with increased expres-
sion of proto-oncogenes (25–27) and, as a result, may lead
to abnormalities that contribute to cancer processes.
Here, we show that TTP acts as a positive regulator of
let-7 biogenesis by down-regulating Lin28 expression in
human cancer cells. TTP expression is signiﬁcantly
reduced and negatively correlates with Lin28a expression
in human cancer cells. Lin28a mRNA contains ARE
within the 30-UTR and TTP operates its destabilizing
activity through binding to the ﬁrst ARE in the Lin28a
30-UTR. Through this activity, TTP increases let-7 biogen-
esis, decreases expression of let-7 target genes, and conse-
quently suppresses the proliferation of ovarian cancer
cells. These novel ﬁndings suggest that TTP serves as a
positive regulator of let-7 biogenesis and provides a mech-
anism for the coordinate expression of TTP and let-7
observed in human cancers.
MATERIALS AND METHODS
Cell culture
Human cancer cell lines, AGS, Colo320, HCT116, MCF7,
K562, HepG2, NT2 and PA1 were purchased from the
Korean Cell Line Bank (KCLB-Seoul, Korea). PA1 cells
were cultured in Eagle’s Minimum Essential Medium
(EMEM). AGS, Colo320, MCF7 and K562 cells were
cultured in RPMI 1640 media. HepG2, HCT116 and
NT2 cells were cultured in Dulbecco’s Modiﬁed Eagle
Medium (DMEM). All cell lines were supplemented with
10% FBS (heat-inactivated fetal bovine serum)
(WELGENE, Korea) and were maintained at 37 Ci na
humidiﬁed atmosphere of 5% CO2.
Immunohistochemistry
Immunohistochemical detection of TTP and Lin28a was
performed on a tissue array slide constructed with parafﬁn
sections from 192 cases of ovarian adenocarcinoma,
10 adjacent normal and 6 normal tissues (OV20810,
US Biomax Inc., Rockville, MD, USA). After
deparafﬁnization, primary antibody anti-human TTP
antibody (sc-14030, Santa Cruz Biotechnology) or
anti-human Lin28a antibody (ab46020, Abcam) at a
1:100 dilution was applied for 2 h at room temperature.
Primary antibodies were detected using EnVision
TM+/
HRP kits (DAKO, Carpinteria, CA, USA). Peroxidase
activity was visualized with 3-amino-9-ethyl carbazole
(Sigma). The sections were counterstained with Mayer’s
hematoxylin. Negative controls, in which the primary
antibody incubation step was omitted, were also
included for each staining. The expression of TTP and
Lin28a was scored semi-quantitatively based on the inten-
sity and proportion of staining. Staining intensity was
subclassiﬁed as 0, negative; 1, weak; 2, moderate and 3,
strong. The proportion of staining was scored as 1,
0–25%; 2, 26–50%; 3, 51–75% and 4, 76–100%.
Staining scores were obtained by multiplying staining in-
tensity by the proportion of staining. Two pathologists,
with no prior clinical or pathological information, scored
the expression at 100  magniﬁcation under light micros-
copy. All available areas in the section were evaluated.
Plasmids, siRNAs, transfections and dual-luciferase assay
The pcDNA3/BRF1 and the pcDNA6/V5-TTP constructs
were described previously (28,29). The pcDNA3/
Flag-Lin28a construct was a gift from Dr V. Narry Kim
(Seoul National University, Seoul, Korea). Full-length
cDNA of human CDC34 was ampliﬁed from the cDNA
of PA1 cells using the following PCR primers: 50-CGGG
ATCCATGGCTCGGCCGCTAGTG-30,5 0-CCGCTCG
AGTCAGGACTCCTCCGTGCC-30. The underlined
sequences are restriction enzyme sites. PCR product was
ligated into the BamHI/XhoI sites of pCMVT2B
(Stratagene). PA1 cells were transfected with pcDNA6/
V5-TTP, pcDNA3/Flag-Lin28a and pCMVT2B/CDC34
using the FuGENE6 in vitro transfection reagent
(Roche) or TurboFect
TM in vitro transfection reagent
(Fermentas).
Small interfering RNAs (siRNAs) against human TTP
(TTP-siRNA, sc-36761), human Lin28a (Lin28a-siRNA,
sc-106829) and control siRNA (scRNA, sc-37007) were
purchased from Santa Cruz Biotechnology (Santa Cruz).
Mature let-7b, mature miR26a, antisense oligonucleotides
against let-7b (AS-let-7b, AACCACACAACCUACUAC
CUCA) and scrambled oligonucleotides (scRNA, AGUA
GUAUGUUCCGCUUAUUGAU) were purchased from
ST Pharm. Co., Ltd. (Korea). PA1 cells were transfected
24h after plating using Lipofectamine
TM RNAiMAX
(Invitrogen) and were harvested 48h. The expression
levels of TTP or Lin28 mRNA and protein were
analyzed by RT-PCR or western blots. To monitor trans-
fection efﬁciency, the GFP expression vector pEGFP-N1
(Clontech) was co-transfected with the plasmid construct
or each oligonucleotide. After conﬁrming transfection
efﬁciency (>80%), cells were used for further study.
Two fragments of Lin28a 30-UTR containing AUUUA
pentamer (the ﬁrst and the second AUUUA, respectively)
were PCR ampliﬁed from the cDNA of PA1 cells using the
following primer sets: Frag-AUUUA1 and Frag-AUUUA
2 (Supplementary Table S1). PCR products were inserted
into the XhoI/NotI sites of the psiCHECK2 Renilla/ﬁreﬂy
dual-luciferase expression vector (Promega, Madison, WI,
USA). One oligonucleotide containing the ﬁrst AUUUA
(ARE1) within the Lin28a 30-UTR (Oligo-ARE1W) was
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IA, USA). A mutant oligonucleotides in which the AUUU
A pentamer was substituted with AGCA (Oligo-ARE1M)
(Supplementary Table S1) was also synthesized. The oligo-
nucleotides were ligated into the XhoI/NotI site of the
psiCHECK2 vector.
Full-length of CDC34 30-UTR was ampliﬁed from
the cDNA of PA1 cells using the following PCR
primers: 50-CCGCTCGAGCACCACCAGAATAAACT
T-30,5 0-TAGTTTAGCGGCCGCCTCATAAAGTAGT
TTTAT-30. The underlined sequences are restriction
enzyme sites. PCR products were inserted into the XhoI/
NotI sites of the psiCHECK2 to generate psiCHECK2-
CDC34 30-UTR WT. A mutant of CDC34 30-UTR in
which the UACCUCA sequences within two let-7b
target sites (27 and 69 bases from the start of CDC34
30-UTR) were substituted with UGGGAGG was
generated using psiCHECK2-CDC34 30-UTR WT as a
template and using a QuickChange site-directed mutagen-
esis kit (Stratagene) according to the manufacturer’s in-
struction. Mutagenic primers used for generation of
site-directed mutant of CDC34 30-UTR were as follows:
CDC34 30-UTR-27: 50-GAATAAACTTGCCGAGTTTG
GGAGGCTAGGGCCGGACCC-30,5 0-GGGTCCGGC
CCTAGCCTCCCAAACTCGGCAAGTTTATTC-30;
CDC34 30-UTR-69: 50-CTCCTTAGACGACAGACTGG
GAGGCGGAGGTTTTGTGCTG-30,5 0-CAGCACAAA
ACCTCCGCCTCCCAGTCTGTCGTCTAAGGAG.
For luciferase assays, cells were cotransfected with
various psiCHECK2-Lin28 30-UTR constructs and
pcDNA6/V5-TTP using the TurboFect
TM in vitro trans-
fection reagent (Fermentas). Transfected cells were lysed
with lysis buffer and mixed with luciferase assay reagent
(Promega) and the chemiluminescent signal was measured
in a SpectraMax L Microplate (Molecular Devices,
Sunnyvale, CA, USA). Fireﬂy luciferase was normalized
to Renilla luciferase in each sample. All luciferase assays
reported here represent at least three independent experi-
ments, each consisting of three wells per transfection.
RNP immunoprecipitation assay
RNP complexes were immunoprecipitated after reverse
crosslinking between target RNA and proteins as previ-
ously described (25). Brieﬂy, 1 10
7 cells of PA1 cells were
cotransfected with 10mg of pcDNA6/V5-TTP and
psiCHECK2-Lin28a-Oligo-ARE1W or psiCHECK2-
Lin28a-Oligo-ARE1M. At 24 h after transfection, the
cell suspension was incubated in 1% of formaldehyde
for 20min at room temperature. The reaction was
stopped with 0.25 M of glycin (pH 7.0), and cells were
sonicated in modiﬁed RIPA buffer containing protease
inhibitors (Roche, Indianapolis, IN, USA). RNP
complexes were immunoprecipitated using protein
G-agarose beads preincubated with 1mg of anti-V5
(Invitrogen) or 1mg of isotype control (Sigma, St Louis,
MO, USA). After crosslinking reversion at 70 C for
45min, RNA was isolated from the immunoprecipitates
and treated with DNAse I (Qiagen, Valencia, CA, USA).
cDNA was synthesized from the RNA and Renilla
luciferase gene was ampliﬁed by PCR using Taq
polymerase (Solgent, Daejeon, Korea) and Renilla
luciferase speciﬁc primers (Up-ACGTGCTGGACTCCTT
CATC, Down-GACACTCTCAGCATGGACGA). TTP
proteins in the immunoprecipitated samples were detected
by western blot analysis using an anti-V5 antibody
(Invitrogen).
Electrophoretic mobility shift assay
The biotinylated RNA probes for the wild-type
(Lin28a-ARE1-WT, 50-CCCCAUUCUGGGCCAAUGU
GAUUUUAUUUAUUUGCUCCCUUGGAUACUGC
ACCUU-30) and mutant (Lin28a-ARE1-MUT, 50-CCCC
AUUCUGGGCCAAUGUGAUUUUAGCAUUUGCU
CCCUUGGAUACUGCACCUU-30) constructs were
generated by ST Pharm. Co., Ltd (Korea). A mutant
RNA probe in which one AUUUA pentamer was
substituted with AGCA was used as a negative control.
Cytoplasmic extracts were prepared from HCT116 cells
and TTP-transfected PA1 cells using NE-PER nuclear
and cytoplasmic extraction reagents (Thermo Pierce
Biotechnology Scientiﬁc, Rockford, IL, USA).
Electrophoretic mobility shift assay (EMSAs) were per-
formed using the LightShift
TM Chemiluminescent EMSA
kit (Thermo Pierce Biotechnology Scientiﬁc). Binding re-
actions were conducted using 80.0fmol of biotinylated
RNA and 3.0mg of cytoplasmic protein cellular extract
in a binding buffer. For EMSA supershifts, anti-TTP
antibody (ab36558, Abcam), anti-V5 antibody (20-783-
70389, GenWay) or control antibody (I-5381, Sigma)
was added to the reaction mixture. After addition of
antibodies, reaction mixtures were incubated overnight
on ice and resolved on 5% non-denaturing polyacrylamide
gels in 0.5  Tris borate/EDTA buffer. Gels were
transferred to nylon membrane (Hybond
TM-N
+) in 0.5 
Tris borate/EDTA at 70V for 40min. Transferred
RNAs were cross-linked to the membrane and detected
using horseradish peroxidase-conjugated streptavidin
(LightShift
TM Chemiluminescent EMSA kit) according
to the manufacturer’s instructions.
SDS–PAGE analysis and immunoblotting
Proteins were resolved by SDS–PAGE, transferred onto
Hybond-P membranes (Amersham Biosciences Inc.), and
probed with appropriate dilutions of rabbit anti-human
TTP antibody (ab36558, Abcam), anti-human Lin28a
antibody (ab46020, Abcam), anti-Lin28b (sc-130802,
Santa Cruz Biotechnology), anti-Drosha antibody
(#3364s, Cell Signaling), anti-Dicer antibody (sc-30226,
Santa Cruz Biotechnology), anti-Ago2 antibody
(#2897s, Cell Signaling), anti-BRF1 antibody (ab42473,
Abcam), anti-CDC34 antibody (sc-5616, Santa Cruz
Biotechnology), anti-COX-2 antibody (160106,
Cayman), anti-c-Fos antibody (PC38, Calbiochem),
anti-c-Myc antibody (1472-1, Epitomics), anti-K-Ras
antibody (sc-30, Santa Cruz Biotechnology) and anti-
cyclin D antibody (sc-246, Santa Cruz Biotechnology).
Immunoreactivity was detected using the ECL detection
system (Amersham Biosciences Inc.). Films were exposed
at multiple time points to ensure that the images were not
saturated. If required, the band densities were analyzed
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with the densities of internal control b-actin bands.
RNA kinetics, quantitative real-time PCR and
semi-qRT-PCR
For RNA kinetic analysis, we used actinomycin D and
assessed Lin28a mRNA expression by quantitative
real-time PCR (qRT-PCR). Three micrograms of DNase
I-treated total RNA was reverse transcribed using oligo-
dT and Superscript II reverse transcriptase (Invitrogen)
according to the manufacturer’s instructions. qRT-PCR
was performed by monitoring the increase in ﬂuorescence
in real-time of the SYBR Green dye (QIAGEN, Hilden,
Germany) using StepOnePlus
TM Real-time PCR systems
(Applied Biosystems). Semi-qRT-PCR was performed
using Taq polymerase (Solgent, Daejeon, Korea) and
PCR primer pairs (Supplementary Table S1). mRNA
half-life was calculated from the non-linear regression of
the mRNA levels at 0-, 30- and 60-min time points fol-
lowing addition of actinomycin D using GraphPad Prism
4.00 software based on a one-phase exponential decay
model.
miRNA analysis
Total RNA was isolated with Trizol reagent (Ambion).
Quantitative levels of mature let-7a, let-7b, let-7f, let-7g,
miR-16, miR302b and RNU6B were determined using
TaqMan MicroRNA Assay kits (let-7a-000377,
let-7b-002619, let-7f-000382, let-7g-002282, miR-16-
000391, miR-302b-000531 and RNU6B-001093, Applied
Biosystems) according to the manufacturer’s protocol.
Mature microRNAs and RNU6B were detected using
StepOne Plus by monitoring in real-time the increase in
ﬂuorescence of TaqMan probe-based detection (Applied
Biosystem). To determine the expression levels of pri-let-7
and pre-let-7, qRT-PCR was performed using EvaGreen
qPCR Mastermix (Applied Biological Materials Inc.),
StepOne Plus
TM Real-time PCR systems (Applied
Biosystems) and the primers sets for pri-let-7a,
pre-let-7a, pri-let-7b, pre-let-7b, pri-let-7f, pre-let-7f,
pri-let-7g and pre-let-7g (Supplementary Table S1).
Cell viability/proliferation
For the MTS cell proliferation assay, PA1 cells were
plated in triplicate at 1.0  10
4cells/well in 96-well
culture plates in EMEM media. At 24h after plating,
CellTiter 96 AQueous One solution reagent (Promega)
was added to each well according to the manufacturer’s
instructions, and absorbance at 490nm was determined
for each well using a Victor 1420 Multilabel Counter
(EG&G Wallac, Turku, Finland).
Statistical analysis
For statistical comparisons, P values were determined
using Student’s t-test or one-way ANOVA.
RESULTS
TTP positively regulates let-7 expression in human
cancer cells
Both the TTP ARE-binding protein and the let-7 miRNA
contribute to the post-transcriptional regulation of genes
as the expression of both TTP and let-7 are often repressed
in human cancers (9,24,30). Thus, it is highly possible that
there are links between their expressions in cancer cells.
We initially sought to determine whether overexpression
of TTP could affect the biogenesis of let-7 in human
cancer cells. TTP expression levels were examined by
western blotting in four human cancer cell lines including
PA1 (ovarian cancer), HCT116 (colorectal cancer),
Colo320 (colorectal cancer) and AGS (stomach cancer)
cells. The expression level of TTP was high in HCT116
and AGS and low in PA1 and Colo320 cells (Figure 1A).
The ovarian cancer PA1 cells with low expression level of
endogenous TTP were transfected with pcDNA6/V5-TTP
(PA1/TTP) or the control pcDNA6/V5 vector (PA1/
pcDNA) and we analyzed the levels of endogenous let-7
in PA1/TTP and PA1/pcDNA cells by quantitative
RT-PCR (qRT-PCR). Overexpression of TTP in PA1/
TTP cells was conﬁrmed by western blots (Figure 1B),
and overexpression of TTP increased the levels of
mature let-7a, let-7b, let-7f and let-7g miRNAs in PA1/
TTP cells (Figure 1C). Notably, these changes were not
attributed to different rates of let-7 transcription, as the
levels of both pri- and pre-let-7 transcripts were compar-
able between PA1/TTP and PA1/pcDNA cell lines
(Figure 1C). To determine whether TTP overexpression
affects the level of other miRNAs, we analyzed the levels
of mature miR-16 and miR-302b in PA1/TTP and PA1/
pcDNA cells by quantitative RT-PCR (qRT-PCR). TTP
overexpression did not affect the levels of both miR-16
and miR-302b (Supplementary Figure S1), suggesting the
speciﬁc effect of TTP on let-7. These results indicate that
TTP regulates let-7 biogenesis in PA1 cells at the
post-transcriptional level.
TTP regulates the expression level of the let-7 target
gene CDC34
Our next goal was to determine whether TTP controls the
expression levels of let-7 target genes. It has been reported
that let-7 functions as a tumor suppressor by down-
regulating K-Ras, cyclin D, CDC34 and c-Myc, as well
as several genes involved in cell cycle and cell division
control (31–34). To determine the effects of TTP
overexpression on the expression of let-7 target genes,
we analyzed the expression level of K-Ras, cyclin D,
CDC34 and c-Myc by RT-PCR and western blots in
PA1 cells transfected with pcDNA6/V5-TTP or the
control pcDNA6/V5 vector. We also analyzed the expres-
sion level of TTP-target genes including VEGF, COX2 and
c-Fos genes (26,27,29). Interestingly, while overexpression
of TTP resulted in signiﬁcant decrease in the expression
level of CDC34 (Figure 2A and B), it did not affect the
expression level of any of the other genes (Supplementary
Figure S2). Down-regulation of CDC34 by TTP
overexpression was conﬁrmed by semi-quantitative
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western blots (Figure 2A, bottom panel) and qRT-PCR
(Figure 2B). Coinciding with a previous report (34), trans-
fection of let-7b decreased the level of CDC34 (Figure 2C
and D). On the contrary, down-regulation of let-7b by
treatment with anti-let-7b oligonucleotides (AS-let-7b)
(Figure 2E), which act as competitive inhibitors of
let-7b, attenuated the TTP-induced decrease of CDC34
(Figure 2F). To determine whether the inhibitory effect
of TTP on CDC34 is mediated by increased let-7b,w e
prepared a luciferase reporter gene linked to the
wild-type CDC34 30-UTR (CDC34 30-UTR WT) or
mutant CDC34 30-UTR (CDC34 30-UTR MUT) with
point mutations in let-7b target sites in the CDC34
30-UTR. Let-7b was also used as a control. While TTP
overexpression or let-7b treatment signiﬁcantly decreased
the luciferase activity of luciferase reporter gene contain-
ing wild-type CDC34 30-UTR, it did not affect that con-
taining mutant CDC34 30-UTR (Figure 2G). Collectively,
these results indicate that TTP inhibits CDC34 expression
and let-7b mediates the effect.
Overexpression of CDC34 attenuates the inhibitory effect
of TTP on the growth of PA1 cells
We next examined whether TTP overexpression affects the
proliferation of PA1 cells in vitro. PA1 cells were trans-
fected with pcDNA6/V5-TTP or pcDNA6/V5 and we
evaluated the effects of TTP overexpression on cellular
metabolic activity using MTS cell proliferation assay.
The results showed that TTP overexpression decreased
the MTS value (Figure 3A). It has been reported that
TTP overexpression can induce apoptosis (35). However,
overexpression of TTP did not induce apoptosis in PA1
cells (Supplementary Figure S3), indicating that decrease
in the MTS value is resulted from TTP-induced suppres-
sion of the cell growth. TTP expression can suppress
cell growth through destabilization of VEGF, COX2,
and c-Fos, c-Myc, and cyclin D mRNAs (26,27,29).
However, as shown in Supplementary Figure S2, there
was no difference in expression of these genes between
PA1/pcDNA and PA1/TTP cells. Also, TTP over-
expression did not lead to a change in the expression
level of several genes involved in the control of cell cycle
such as CCNA1, CCNB1, CCNB2, CCND1, CCND2,
CCND3 and CDK2 (Supplementary Figure S2). CDC34
is an E2 ubiquitin-conjugating enzyme that supports cell
growth by facilitating the proteasome-mediated degrad-
ation of multiple cell cycle regulators (36). To determine
whether the TTP-induced inhibition of cell growth was
mediated by a reduction in CDC34 levels, we transfected
PA1 cells with CDC34 cDNA, whose expression is not
affected by TTP and let-7b because the transcript does
not contain a CDC34 30-UTR. Overexpression of
CDC34 (Figure 3B and C) increased the growth of PA1/
TTP to 92% of PA1/pcDNA (Figure 3D). These results
show that TTP expression suppresses the growth of PA1
cells through down-regulation of CDC34.
TTP down-regulates the expression of Lin28
TTP overexpression did not affect the levels of pri- and
pre-let-7b but increased mature let-7b level (Figure 1C).
Thus, we hypothesized that TTP controls let-7b biogenesis
by modulating the expression level of proteins involved in
the post-transcriptional regulation of let-7b biogenesis.
The core components involved in the post-transcriptional
regulation of miRNA biogenesis are Drosha, Dicer,
Argonaute (AGO) and Lin28 (6); as such, we analyzed
the levels of these known let-7b regulatory factors in
PA1/TTP and PA1/pcDNA cells. Western blot analysis
revealed that while TTP overexpression did not affect
the levels of Drosha, Dicer and AGO, it decreased the
expression of the negative regulatory factor Lin28a
(Figure 4A). TTP-induced reduction of Lin28a level was
conﬁrmed by semi-qRT-PCR (Figure 4B) and qRT-PCR
(Figure 4C). TTP also decreased Lin28b level in PA1 cells
(Figure 4D).
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Figure 1. TTP positively regulates the level of mature let-7 in cells. (A) TTP protein level in human cancer cell lines measured by western blot assays.
PA1 cells with low TTP expression and HCT116 cells with high TTP expression were selected for further study. (B and C) Overexpression of TTP
increases the levels of let-7. PA1 cells were transiently transfected with pcDNA6/V5-TTP (PA1/TTP) or empty vector pcDNA6/V5 (PA1/pcDNA) for
24h. (B) TTP protein levels determined by western blot assays. Cell lysate from HCT116 cells was included as a positive control. (C) Levels of pri-,
pre- and mature-miRNA of let-7 were determined by quantitative RT-PCR (qRT-PCR). The levels obtained from PA1/pcDNA were set to 1.0.
Results shown represent the means±SD of three independent experiments (*P<0.05; **P<0.01).
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on the expression level of Lin28a. The expression level of
TTP in PA1 cells was extremely low (Figure 1A) and thus
this cell line was not suitable for TTP knockdown studies.
Instead, the human colon cancer HCT116 cell line that
expressed high levels of TTP was used for TTP
knockdown experiments. The inhibition of TTP by
siRNA (Figure 4E and G) increased Lin28a level in
HCT116 cells (Figure 4F and G). We also determined
the effects of TTP inhibition on the expression levels
of let-7b, let-7b target genes and cell growth.
Down-regulation of TTP decreased the let-7b level
(Figure 4H), increased the let-7b target gene, CDC34
and cell growth (Figure 4G and I). Collectively, our
results suggest that TTP down-regulates Lin28a expres-
sion in cancer cells.
Expression of TTP is inversely correlated with Lin28a in
human cancer cell lines and ovarian adenocarcinoma
tissues
To determine if TTP expression is inversely correlated
with Lin28a expression in human cancer cell lines, we
analyzed the expression of TTP and Lin28a in seven
human cell lines: PA1, MCF7 (breast adenocarcinoma),
AGS, K562 (erythroleukemia), HepG2 (hepatocellular
carcinoma) and NT2 (neuron-committed teratocarcin-
oma). While cell lines with low TTP levels showed high
expression levels of Lin28a, those with high TTP levels
showed a low level of Lin28a (Figure 4J), suggesting an
inverse correlation between TTP expression and Lin28a
expression in human cancer cell lines.
Next, we investigated the expression of TTP and Lin28a
proteins in 192 ovarian adenocarcinoma, 10 adjacent
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Figure 2. TTP negatively regulates the expression of the let-7b target gene CDC34.( A and B) Overexpression of TTP downregulates CDC34 levels.
The levels of CDC34 in PA1 cells transfected with pcDNA6/V5-TTP and pcDNA6/V5 was determined by semi-qRT-PCR (A, top panel), western
blots (A, bottom panel) and qRT-PCR (B). The data represent the mean±SD of 3 independent experiments (*P<0.05). (C and D) Overexpression
of let-7b suppresses CDC34 expression. PA1 cells were transfected with 50nM of let-7b or scrambled miRNA oligonucleotides for 24h. (C) The levels
of let-7b was determined by qRT-PCR. The levels obtained from mock-treated cells (PA1/Mock) were set to 1.0. Data are presented as the
mean±SD (n=3) (***P<0.001). (D) CDC34 protein levels were measured by western blot assays. (E and F) Knockdown of let-7b abolishes
the suppression of CDC34 expression induced by TTP. PA1 cells were cotransfected with pcDNA6/V5-TTP, anti-let-7b oligonucleotides (AS-let-7b)
or scrambled oligonucleotides (scRNA) for 24h. (E) The level of let-7b was determined by qRT-PCR. The levels of let-7b in PA1 cells transfected
with pcDNA and scRNA oligonucleotides were set to 1.0. Data are presented as the mean±SD (n=3) (**P<0.01). (F) The level of CDC34 was
determined by western blot assays. (G) Down-regulation of CDC34 by TTP is mediated by let-7b. PA1 cells were transfected with various com-
bination of pcDNA6/V5, pcDNA6/V5-TTP, psiCHECK2-CDC34 30-UTR WT, psiCHECK2-CDC34 30-UTR MUT and let-7b for 24h. After
normalizing luciferase activity, the luciferase activity obtained from PA1 cells co-transfected with the pcDNA6/V5 and psiCHECK2-CDC34
30-UTR WT was set to 1.0. Results shown represent the means±SD of three independent experiments (**P<0.01). ns, not signiﬁcant.
Nucleic Acids Research,2012, Vol.40, No. 9 3861normal and 6 normal tissues by immunohistochemical
staining. TTP expression was high in normal ovarian
tissues (mean staining score, 6.23±0.40) but low in
ovarian adenocarcinoma (mean staining score,
2.66±0.18; P<0.0001). On the contrary, Lin28a expres-
sion was extremely low in normal ovarian tissues (mean
staining score, 0.52±0.03) and high in ovarian adenocar-
cinoma (mean staining score, 5.43±0.26; P<0.0001)
(Figure 4K and Table 1). There were no signiﬁcant differ-
ences in TTP and Lin28a expression according to tumor
stage (Table 1). These results show that Lin28a expression
is inversely correlated with TTP in ovarian
adenocarcinoma.
TTP destabilizes Lin28a mRNA
To determine whether decreased expression of Lin28a
resulted from changes in the stability of Lin28a mRNA,
the half life of this mRNA was calculated from the mRNA
levels measured by qRT-PCR in PA1 cells transfected with
pcDNA6/V5-TTP or control pcDNA6/V5 vector.
Overexpression of TTP protein in PA1/TTP cells was con-
ﬁrmed by western blot analysis (Figure 5A). In the control
PA1/pcDNA cells, Lin28a mRNA was stable for 2h after
actinomycin D treatment. However, in PA1/TTP cells, the
half-life of Lin28a mRNA was 1h 30min (Figure 5B). We
also determined the half-life of Lin28a mRNA in HCT116
cells treated with siRNA against TTP (HCT116/
TTP-siRNA) or control siRNA (HCT116/scRNA). In
the control HCT116 and HCT116/scRNA cells, the
half-life of Lin28a mRNA was 40min. However, in
HCT116/TTP-siRNA cells, Lin28a mRNA was stable
until 3h after actinomycin D treatment (Figure 5C). To
determine whether regulation of Lin28a mRNA decay by
TTP is biologically important, we compared the Lin28a
mRNA half-life between HCT116 with high TTP levels
and PA1 with low TTP level. As shown in Figure 5D,
the half-life of Lin28a mRNA in PA1 cells was longer
(t
1/2=4h50min) than that in AGS cells (t
1/2=35min).
These results indicate that the TTP expression contributes
to a decrease in Lin28a levels through destabilization of
Lin28a mRNA.
TTP decreases the expression of luciferase mRNA
containing the Lin28 30-UTR
TTP protein regulates mRNA stability through binding
AREs within the mRNA 30-UTR (22,23,29). Analysis of
the 3259-bp human Lin28a 30-UTR revealed the presence
of two pentameric AUUUA motifs (Figure 5E). To deter-
mine whether down-regulation of Lin28a expression by
TTP is mediated through the Lin28a mRNA 30-UTR, we
made use of a luciferase reporter gene linked to the Lin28a
30-UTR fragments containing each pentameric AUUUA
motif; Frag-AUUUA1 (containing the ﬁrst pentameric A
UUUA) and Frag-AUUUA2 (second pentameric AUUU
A) in the plasmid psiCHECK2 (Figure 5E). When PA1
cells were transfected to overexpress TTP (Figure 5A),
luciferase activity from Frag-AUUUA1 was inhibited;
however, Frag-AUUUA2 did not respond to TTP
(Figure 5F, left panel). The results suggest that the
Frag-AUUUA1 within the Lin28a 30-UTR is responsible
for destabilization of Lin28a mRNA by TTP. To deter-
mine the importance of the ﬁrst AUUUA pentamer
(ARE1) within Frag-AUUUA1, we prepared luciferase
reporter genes containing wild-type (Oligo-ARE1W, con-
taining wild-type ARE1) and mutant (Oligo-ARE1M,
containing AUUUA sequences substituted with AGCA)
oligonucleotides (Figure 5E). While Oligo-ARE1W
responded to TTP (60% inhibition), Oligo-ARE1M did
not respond to TTP (Figure 5F, right panel). These
results strongly suggest that the ﬁrst AUUUA pentamer
within the Lin28a 30-UTR is involved in TTP inhibitory
activity in PA1 cells. Lin28b mRNAs also contain AUUU
A pentamers within their 30-UTR and TTP can
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Figure 3. Transfection of CDC34 cDNA without the 30-UTR (or overexpression of CDC34) attenuates the inhibitory effect of TTP on the growth of
PA1 cells. (A) Overexpression of TTP suppresses the growth of PA1 cells. PA1 cells transfected with pcDNA6/V5-TTP or pcDNA6/V5 were seeded
at 1.0 10
4 cells per well in 96-well plates. Cell viability was assessed at 24h after seeding by measuring absorbance at 490nm using a MTS cell
proliferation assay. The values obtained from PA1/Mock cells were set to 1.0. The data represent the mean±SD of three independent experiments
(***P<0.001). ns, not signiﬁcant. (B–D) Transfection of CDC34 cDNA without 30-UTR abrogates the suppressive effect of TTP on PA1 growth.
PA1 cells were transfected with a combination of pcDNA6/V5-TTP and pCMVT2B/CDC34 for 24h. (B) The levels of TTP and CDC34 proteins
were measured by western blot assays. (C) CDC34 levels were measured by qRT-PCR. The levels obtained from PA1/pcDNA cells were set to 1.0.
Data are presented as the mean±SD (n=3) (**P<0.01; ***P<0.001). (D) Cell viability was assessed by measuring absorbance at 490nm using a
MTS cell proliferation assay. The levels obtained from PA1/pcDNA cells were set to 1.0. Data are presented as the mean±SD (n=3) (**P<0.01).
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Figure 4. TTP negatively regulates the levels of Lin28a in human cancer cells. (A–D) Overexpression of TTP inhibits Lin28a levels in PA1 cells. PA1
cells were transfected with pcDNA6/V5-TTP or pcDNA6/V5 for 24h. (A) The levels of TTP, Drosha, Dicer, Ago2 and Lin28a proteins were
determined by western blot assays. (B) The expression levels of TTP and Lin28a were determined by semi-qRT-PCR. (C) The level of Lin28a was
determined by qRT-PCR. The levels obtained from PA1/pcDNA cells were set to 1.0. Data are presented as the mean±SD (n=3) (**P<0.01).
(D) Overexpression of TTP decreases Lin28b levels in PA1 cells. The level of TTP and Lin28b were determined by RT-PCR (top panel) and western
blot (bottom panel). (E–I) Downregulation of TTP by siRNA increases Lin28a levels and decreases let-7b in HCT116 cells. HCT116 cells were
transfected with TTP-speciﬁc (TTP-siRNA) or scRNA. After 24h, the levels of TTP and Lin28a were determined by qRT-PCR (E and F) and
western blot assays (G). The level of let-7b was determined by qRT-PCR (H) and cell viability was assessed by measuring absorbance at 490nm using
a MTS cell proliferation assay (I). The levels obtained from mock-transfected HCT116 cells were set to 1.0. Data are presented as the mean±SD
(n=3) (**P<0.01; ***P<0.001). ns, not signiﬁcant. (J) The level of TTP protein is inversely correlated with those of Lin28a protein within several
human cell lines. Levels of TTP and Lin28a proteins were determined by western blot analysis in PA1 (ovarian teratocarcinoma), MCF7 (breast
adenocarcinoma), AGS (gastric adenocarcinoma), K562 (erythroleukemia), HepG2 (hepatocellular carcinoma) and NT2 (neuronally committed
teratocarcinoma) cells. b-Actin was detected as the loading control. (K) TTP expression level is inversely correlated with that of Lin28a in
human ovarian tissues. Representative TTP and Lin28a immunohistochemical staining in normal and ovarian adenocarcinoma tissues. Normal
ovarian tissues showed strong immunoreactivity for TTP, where as the ovarian adenocarcinoma showed strong positive staining for Lin28a.
Nucleic Acids Research,2012, Vol.40, No. 9 3863down-regulate a luciferase reporter gene containing the
Lin28b 30-UTR at its 30-end (Figure 5G and H).
TTP binds to the ﬁrst AUUUA pentamer within the
Lin28a mRNA 30-UTR
To determine whether TTP interact with ARE1 of Lin28a
30-UTR, PA1 cells were cotransfected with pcDNA6/
V5-TTP (V5-TTP) and psiCHECK2-Lin28a-Oligo-
ARE1W (wild-type ARE1) or psiCHECK2-Lin28a-
Oligo-ARE1M (mutant ARE1). After immunopre-
cipitation with anti-V5 or control antibody, the presence
of TTP was determined by western blot using an anti-V5
antibody (Figure 5I). Total RNA was extracted from the
immunoprecipitates and the presence of luciferase mRNA
was analyzed by RT-PCR using PCR primers speciﬁc to
the luciferase gene. The ampliﬁed PCR product was
observed in immunoprecipitates from cells transfected
with psiCHECK2-Lin28a-Oligo-ARE1W and pcDNA6/
V5-TTP (Figure 5I). However, PCR product was not
detected in samples from cells transfected with
psiCHECK2-Lin28-Oligo-ARE1M and pcDNA/TTP
(Figure 5I). PCR product was not also detected in
immunoprecipitates obtained using control antibody.
These results demonstrate that TTP interacts speciﬁcally
with the Lin28a ARE1.
To conﬁrm the interaction of TTP with the ARE1 of the
Lin28a 30-UTR, RNA EMSA was conducted using a
biotinylated RNA probe containing the wild-type or
mutant ARE1 of Lin28a . The RNA probes used for
RNA EMSA were the same as those used for the
luciferase assay. Cytoplasmic extracts were prepared
from PA1 cells transfected with pcDNA6/V5-TTP and
incubated with biotinylated RNA probe containing the
wild-type or mutant ARE1 of Lin28a 30-UTR. When
RNA EMSA was conducted using the wild-type
Lin28a-ARE1 probe, a dominant RNA-protein complex
was observed; however, mutant Lin28a-ARE1 prevented
the formation of this complex. Complex formation was
supershifted with an anti-V5 antibody (Figure 5J). Next,
we determined the association between endogenous TTP
and Lin28a-ARE1. For this purpose, we used high
TTP-expressing HCT116 cells (Figure 1A). When the
wild-type Lin28a-ARE1 probe was mixed with cytoplas-
mic extracts from HCT116 cells, a dominant
probe-protein complex was observed (Figure 5K) while
the mutant Lin28a-ARE1 probe failed to form the
complex. Formation of the Lin28a-ARE1 probe-protein
complex was reduced by preincubation of the reaction
mixture with an anti-TTP antibody but not with a
control antibody (Figure 5K). Taken together, these
data strongly suggest that repression of Lin28a occurs
through interaction of TTP with the ARE1 of Lin28a
30-UTR.
Overexpression of Lin28a attenuates the inhibitory effects
of TTP on let-7b expression and cell growth
Based on our results, it was speculated that TTP induces
let-7b level through down-regulation of Lin28a. To
conﬁrm this hypothesis, we ﬁrst determined whether
knockdown of Lin28a by siRNA enhanced let-7b expres-
sion in PA1 cells. Western blot analysis conﬁrmed the in-
hibition of Lin28a expression in PA1 cells (PA1/
Lin28a-siRNA) by siRNA treatment (Figure 6A). As
expected, let-7b expression level in PA1/Lin28a-siRNA
was increased compared to PA1 cells treated with
control siRNA (PA1/scRNA) (Figure 6B). In addition,
inhibition of Lin28a decreased the level of CDC34
(Figure 6C). To conﬁrm the involvement of Lin28a for
the TTP-induced increase of let-7b level, we co-transfected
PA1 cells with pcDNA6/V5-TTP and pcDNA3/
Flag-Lin28a, which does not contain the Lin28a
30-UTR. At 24-h post-transfection, cells were analyzed
for the expression of let-7b, CDC34 and proliferation.
Overexpression of Lin28a (Figure 6D) abrogated the
effect of TTP on the expression of let-7b and CDC34
(Figure 6E). In addition, overexpression of Lin28a
restored the growth of PA1/TTP to 87% of PA1/
pcDNA (Figure 6F). These results indicate that TTP
affects the expression level of let-7b and CDC34 and
the cell growth through down-regulation of Lin28a in
PA1 cells.
DISCUSSION
The miRNA let-7 controls the expression of multiple
oncogenes in cancer cells. As such, understanding the
regulation of let-7 expression is crucial as alteration of
let-7 expression has been linked to human diseases,
including several cancers (9). TTP is an ARE-binding
protein that promotes destabilization of ARE-containing
mRNAs (22,23,29). Here, we described a role for TTP in
the regulation of let-7 expression. When we overexpressed
TTP in cancer cells, expression level of let-7 was increased.
On the contrary, down-regulation of TTP decreased the
let-7 level. Thus, our data indicate that TTP is a positive
regulator for let-7 expression.
Regulation of let-7 expression occurs at both the tran-
scriptional and post-transcriptional levels. It is likely that
TTP regulates let-7 expression post-transcriptionally, as
TTP did not affect the level of pri-let-7 but affected the
level of mature let-7. Post-transcriptional regulation
Table 1. TTP and Lin28a expression and clinicopathologic features
of patients with ovarian adenocarcinoma
N TTP Lin28a
Staining
score
a
P-value Staining
score
a
P-value
Disease index
Adenocarcinoma 182 2.66±0.18 <0.0001 5.43±0.26 <0.0001
Normal 16 6.23±0.40 0.52±0.03
Tumor stage
I 132 2.79±0.22 0.306** 5.60±0.31 0.594**
II 26 2.15±0.39 5.04±0.68
III 15 3.06±0.76 4.67±0.84
IV 9 1.56±0.47 5.33±1.15
aMean±SEM.
**P-values were determined using one-way ANOVA.
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Figure 5. TTP enhances the decay of Lin28a mRNA through interaction with an ARE within the Lin28a mRNA 30-UTR. (A and B) TTP desta-
bilizes Lin28a mRNA. PA1 cells were transfected with pcDNA6/V5-TTP or pcDNA6/V5 for 24h. (A) The level of TTP protein was determined by
western blot assays. (B) Expression of Lin28a mRNA in PA1 cells was determined by qRT-PCR and mRNA half-life was calculated from the
non-linear regression of the mRNA levels at the indicated times after the addition of 5.0mg/ml actinomycin D. A one-phase model of exponential
decay was used to derive the indicated mRNA decay curves. Results shown on the graph represent the means±SD of three independent experiments
(**P<0.01; ***P<0.001). (C) Inhibition of TTP by siRNA enhances Lin28a mRNA stability. HCT116 cells were transfected with siRNA against
TTP-speciﬁc (TTP-siRNA) or scRNA for 24h. Expression of Lin28a mRNA in HCT116 cells was determined by qRT-PCR and mRNA half-life was
calculated as described in (B). Results shown on the graph represent the means±SD of three independent experiments (*P<0.05). (D) Lin28a
mRNA half-life in PA1 cell with low TTP level is longer than that in AGS cells with high TTP level. Expression of Lin28a mRNA in PA1 and AGS
cells was determined by qRT-PCR and mRNA half-life was calculated as described in (B). Results shown on the graph represent the means±SD of
three independent experiments (***P<0.001). (E and F) The ﬁrst AUUUA pentamer (ARE1) within the Lin28a 30-UTR is essential for the
inhibitory effect of TTP. (E) Schematic representation of the luciferase reporter constructs used in this study. Fragments (Frag) and oligonucleotides
(Oligo) derived from the Lin28a mRNA 30-UTR were cloned downstream of the luciferase reporter gene in the psiCHECK2 luciferase expression
vector. White circles, wild-type (W) pentameric motif AUUUA; gray circles, mutated (M) motif AGCA. (F) PA1 cells were co-transfected with
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(continued)occurs at multiple steps of miRNA biogenesis (5,6).
Recently, the Lin28 proteins have been identiﬁed as
negative regulatory factors for let-7 biogenesis (12–14).
We provided several lines of evidence that TTP enhances
let-7b expression by down-regulation of Lin28a expres-
sion. First, Lin28a mRNA contains ARE within its
30-UTR and TTP binds to the ARE of Lin28a mRNA;
second, TTP enhances the decay of Lin28a mRNA and
a luciferase reporter gene containing the Lin28a 30-UTR at
its 30-end. Overexpression of Lin28a, whose transcript
does not contain a Lin28a 30-UTR, attenuates the
increase of let-7b induced by TTP. So, our data suggest
that TTP interacts with the 30-UTR of Lin28a mRNA to
enhance the decay of Lin28a mRNA, leading to increased
expression of let-7b. An inverse correlation was noted
between the expression levels of TTP and Lin28a in
tissues of ovarian adenocarcinoma, indicating that the
mechanism by which TTP inhibits Lin28a is fundamental-
ly important in cancer.
Based on our results, TTP-induced down-regulation of
Lin28 was followed by the inhibition of cancer cell growth.
In addition to blocking let-7 biogenesis (12–14), Lin28 has
been reported to bind to a speciﬁc subset of mRNAs
including those for IGF-2, Oct4 and several cell
cycle-related factors, thereby modulating their translation
(37–39). The observed growth inhibition following
TTP-mediated Lin28a repression is likely the result of res-
toration in let-7b miRNA expression, which blocks
CDC34 translation, a target mRNA involved in
promoting cell cycle progression (34). We provided
evidence supporting this hypothesis as TTP over-
expression decreased the expression level of CDC34 and
inhibition of TTP by siRNA increased that inhibition.
Overexpression of Lin28a without a 30-UTR blocked the
increase of let-7b, and decrease of CDC34 and inhibition
of cell growth induced by TTP overexpression. Inhibition
of let-7b by antisense treatment attenuated the decrease
of CDC34 induced by TTP overexpression and
overexpression of the CDC34 ORF without a 30-UTR
attenuated the inhibitory effect of TTP on the cell
growth. Interestingly, antisense oligonucleotide in
TTP-overexpressing cells did not reduce the let-7b level
to that of mock-transfected cells (Figure 2E), suggesting
that TTP might inhibit the antisense-mediated silencing of
let-7b by regulating the expression and/or activity of
factors involved in let-7b degradation. CDC34 may not
be the only gene whose expression is affected by TTP, as
the expression level of another let-7b target gene, HMGA2
(40) was affected by TTP level (Supplementary Figure S4).
These data indicate that TTP can control cell growth by
regulating miRNA target genes as well as ARE-containing
genes.
There are many ARE-binding proteins that can affect
the decay of ARE-containing mRNA (41,42). However,
it is not likely that all ARE-binding proteins affect the
stability of Lin28 mRNA, as overexpression of
ARE-binding protein BRF1 did not affect the expression
level of the Lin28a (Supplementary Figure S5). The
precise mechanism of TTP-speciﬁc targeting of Lin28a
mRNA remains elusive. Further studies on proteins
required for the function of TTP and other
ARE-binding proteins will reveal the mechanism(s) for
this speciﬁcity.
Recent studies have indicated a connection between
ARE-binding proteins and miRNAs (43,44). A few cases
of cooperative (43,45) and competitive (46) binding have
been described as involved in ARE-containing mRNA
decay. TTP was shown to interact with the RNA-
induced silencing complex (RISC) to facilitate miR-16 tar-
geting of ARE, leading to ARE-mRNA decay (43). When
let-7 binds to adjacent sites of ARE, HuR cooperates with
the let-7 miRNA to repress the expression of MyC tran-
scripts (45). The miR-122 miRNA binds to the 30-UTR of
CAT-1 mRNA and induces mRNA degradation, but
binding of HuR to the CAT-1 30-UTR protects CAT-1
mRNA from miR-122-induced degradation (46). The
KH-type splicing regulatory protein (KSRP), which is
an ARE-binding protein, binds to the terminal loop of
the precursors of a subset of miRNAs as a component
of both Drosha and Dicer to promote their maturation
(47). Here, our results provide a novel mechanism by
which TTP regulates let-7 biogenesis and, combined with
previous reports, suggests that ARE-binding proteins are
closely connected with miRNAs in post-transcriptional
regulation of gene expression.
Figure 5. Continued
pcDNA6/V5-TTP and a psiCHECK2 luciferase reporter constructs containing fragments (left panel) or oligonucleotides (right panel) derived from
the Lin28a mRNA 30-UTR as described in (E) for 24h. After normalizing luciferase activity, the luciferase activity obtained from PA1 cells
transfected with the Frag-ARE1 luciferase construct alone or Oligo-ARE1W alone were set to 1.0. Results shown represent the means±SD of
three independent experiments (*P<0.05; **P<0.01). ns, not signiﬁcant. (G and H) TTP decreases the luciferase activity of luciferase reporter gene
containing the Lin28b 30-UTR. (G) Schematic representation of the luciferase reporter constructs used in this study. Fragments (Frag) derived from
the Lin28b mRNA 30-UTR were cloned downstream of the luciferase reporter gene in the psiCHECK2 luciferase expression vector. White circles,
wild-type pentameric motif AUUUA. (H) PA1 cells were co-transfected with pcDNA6/V5-TTP and a psiCHECK2 luciferase reporter constructs
containing fragments derived from the Lin28b mRNA 30-UTR as described in (G) for 24h. After normalizing luciferase activity, the luciferase
activity obtained from PA1 cells transfected with each Frag-ARE luciferase construct alone was set to 1.0. Results shown represent the means±SD
of three independent experiments (**P<0.01; ***P<0.001). (I) Ribonucleoprotein immunoprecipitation assay. PA1 cells were cotransfected with
pcDNA6/V5-TTP and psiCHECK2 luciferase reporter constructs containing Lin28a Oligo-ARE1W. psiCHECK2 luciferase reporter construct con-
taining mutant ARE1, Oligo-ARE1M was used as a negative control. At 24h after transfection, the ribonucleoprotein complexes containing TTP
were immunoprecipitated with protein G-agarose and anti-V5 or a control antibody. The luciferase mRNA in the immunoprecipitates was ampliﬁed
by RT-PCR. The presence of TTP in the immunoprecipitates was detected by western blot with anti-V5 antibody. (J and K) RNA EMSA was
performed by mixing cytoplasmic extracts containing 3.0mg of total protein from pcDNA6/V5-TTP-transfected PA1 cells (J) or HCT116 cells (K)
with 80fmol biotinylated wild-type Oligo-ARE1W (WT) or mutant Oligo-ARE1M (MUT) probe. Anti-V5 (J), anti-TTP (K) or control antibody was
added to the reaction mixtures. Position of the TTP containing bands (TTP) and super-shifted bands (SS) are indicated.
3866 Nucleic Acids Research, 2012,Vol.40, No. 9In conclusion, we have identiﬁed the unique charac-
teristic of TTP as a positive regulator of let-7 biogenesis.
Our study provides a molecular basis for TTP-mediated
regulation of let-7 biogenesis in human cancer cells and
extends our current understanding of ARE-binding
proteins in miRNA biogenesis by revealing a role for
TTP functioning upstream of Lin28. These ﬁndings
that TTP not only mediates the down-regulation of
ARE-containing mRNAs but is also involved in the
upstream regulation of miRNA target genes further
highlights the important role of TTP in human
tumors. There is emerging evidence supporting the role
of Lin28 in stem cell development and differentiation
(48,49). It will therefore be of interest to explore
whether this type of regulatory mechanism is also im-
portant in ES cell biology, cell reprogramming and
development.
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Figure 6. Overexpression of Lin28a attenuates the effects of TTP on let-7b levels, CDC34 levels and PA1 cell growth. (A–C) Downregulation of
Lin28a by siRNA increases let-7b levels but decreases CDC34 levels in PA1 cells. PA1 cells were transfected with Lin28a-speciﬁc (Lin28a-siRNA) or
scRNA for 24h. (A) The level of Lin28a was determined by qRT-PCR (top panel) and western blot assays (bottom panel). The levels obtained from
PA1/scRNA cells were set to 1.0. Data are presented as the mean±SD (n=3) (***P<0.001). (B) The level of mature let-7b was measured by
qRT-PCR. The levels obtained from PA1/scRNA cells were set to 1.0. Data are presented as the mean±SD (n=3) (*P<0.05). (C) The level of
CDC34 was determined by qRT-PCR. The levels obtained from PA1/scRNA cells were set to 1.0. Data are presented as the mean±SD (n=3)
(***P<0.001). (D–F) Transfection of Lin28a cDNA without the 30-UTR abolishes the effects of TTP on expression of let-7b, CDC34 and PA1 cell
growth. PA1 cells were transfected with a combination of pcDNA6/V5-TTP and pcDNA3/Flag-Lin28a for 24h. (D) The levels of TTP and Lin28a
were measured by semi-qRT-PCR (top panel) and western blot assays (bottom panel). (E) The level of let-7b was measured by qRT-PCR. The levels
obtained from PA1/pcDNA cells were set to 1.0. Data are presented as the mean±SD (n=3)(*P<0.05; **P<0.01). (F) Cell viability was assessed
by measuring absorbance at 490nm using a MTS cell proliferation assay. The levels obtained from PA1/pcDNA cells were set to 1.0. Data are
presented as the mean±SD (n=3) (**P<0.01; ***P<0.001).
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